Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from XORTX Therapeutics Inc ( (TSE:XRTX) ).
On May 19, 2025, XORTX Therapeutics Inc. announced a non-brokered private placement to raise up to USD $3 million through the issuance of common share units. The proceeds will be used to advance the company’s programs for gout and for general corporate purposes. This strategic move aims to strengthen XORTX’s financial position and support its ongoing development efforts in the pharmaceutical industry, particularly in the treatment of gout and kidney-related diseases.
The most recent analyst rating on (TSE:XRTX) stock is a Buy with a C$14.00 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on TSE:XRTX Stock
According to Spark, TipRanks’ AI Analyst, TSE:XRTX is a Underperform.
XORTX Therapeutics Inc faces significant challenges with no revenue and consistent losses, leading to a low financial performance score. Technical analysis indicates a neutral to bearish outlook, which, along with poor valuation metrics, weighs down the overall stock score. However, potential advancements in FDA discussions for gout treatment provide a glimmer of hope for future revenue generation, but current financial and compliance risks remain substantial.
To see Spark’s full report on TSE:XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout. The company has three clinically advanced products in development, including XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute kidney and other organ injuries associated with respiratory virus infections. Additionally, XORTX is working on a pre-clinical stage program for Type 2 diabetic nephropathy, targeting aberrant purine metabolism and xanthine oxidase to decrease uric acid production.
Average Trading Volume: 6,226
Technical Sentiment Signal: Sell
Current Market Cap: C$5.46M
For an in-depth examination of XRTX stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue